Lung Transplant Rejection - Pipeline Review, H2 2016

Publication ID: GMD1116018
Publication Date: November 16, 2016
Pages: 69
Publisher: Global Markets Direct
Countries: Global [1]

$2,000.00

Publication License Type *

- SINGLE USER LICENSE (PDF), $2,000.00
- SITE LICENSE (PDF), $4,000.00
- GLOBAL LICENSE (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Diseases [2]
Pharma & Healthcare [3]

Description:

Lung Transplant Rejection - Pipeline Review, H2 2016

Summary


Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively. Lung Transplant Rejection.

Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lung
Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Contents:**

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lung Transplant Rejection Overview 6
Therapeutics Development 7
Pipeline Products for Lung Transplant Rejection - Overview 7
Lung Transplant Rejection - Therapeutics under Development by Companies 8
Lung Transplant Rejection - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Lung Transplant Rejection - Products under Development by Companies 12
Lung Transplant Rejection - Companies Involved in Therapeutics Development 13
Apeptico Forschung und Entwicklung GmbH 13
Dompe Farmaceutici S.p.A. 14
Kamada Ltd. 15
Novartis AG 16
Proteo, Inc. 17
Quark Pharmaceuticals, Inc. 18
Lung Transplant Rejection - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
alpha-1 proteinase inhibitor (human) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
everolimus - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
FX-06 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
QPI-1024 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
QPLI-1 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
R-554 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
R-801 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
reparixin - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
solnatide - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
tiprelestat - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Lung Transplant Rejection - Dormant Projects 61
Lung Transplant Rejection - Product Development Milestones 62
Featured News & Press Releases 62
Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 62
Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 64
Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 65
Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation 65
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 66
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables
Number of Products under Development for Lung Transplant Rejection, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2016 13
Lung Transplant Rejection - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 14
Lung Transplant Rejection - Pipeline by Kamada Ltd., H2 2016 15
Lung Transplant Rejection - Pipeline by Novartis AG, H2 2016 16
Lung Transplant Rejection - Pipeline by Proteo, Inc., H2 2016 17
Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Lung Transplant Rejection - Dormant Projects, H2 2016 61

List of Figures
Number of Products under Development for Lung Transplant Rejection, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Molecule Types, H2 2016 26
Number of Products by Stage and Molecule Types, H2 2016 26

Companies Mentioned:

Apeptico Forschung und Entwicklung GmbH
Dompe Farmaceutici S.p.A.
Kamada Ltd.
Novartis AG
Proteo, Inc.
Quark Pharmaceuticals, Inc.

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other
person or persons.

- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

---

**Source URL:** https://www.marketresearchreports.com/global-markets-direct/lung-transplant-rejection-pipeline-review-h2-2016

**Links**
